Table 1.
Association of USP22, BMI1, and EZH2 expression with patient characteristics in hepatocellular carcinoma
| Variable | All cases | Training set (n=75)
|
Testing set (n=100)
|
||||
|---|---|---|---|---|---|---|---|
| High expression | Low expression | P-valuea | High expression | Low expression | P-valuea | ||
| Age (years) | 0.257 | 0.345 | |||||
| ≥51b | 88 | 4 (5.3%) | 8 (10.7%) | 9 (9%) | 43 (43%) | ||
| <51 | 87 | 32 (42.7%) | 31 (41.3%) | 12 (12%) | 36 (36%) | ||
| Sex | 0.131 | 1 | |||||
| Male | 152 | 9 (12%) | 57 (76%) | 16 (16%) | 70 (70%) | ||
| Female | 23 | 3 (4%) | 6 (8%) | 3 (3%) | 11 (11%) | ||
| Clinical stage | 0.095 | 0.041 | |||||
| I + II | 51 | 1 (1.3%) | 24 (32%) | 2 (2%) | 24 (24%) | ||
| III + IV | 124 | 11 (14.7%) | 39 (52%) | 20 (20%) | 54 (54%) | ||
| Tumor size (cm) | 0.099 | 0.617 | |||||
| ≤5 | 82 | 3 (4%) | 38 (50.7%) | 8 (8%) | 33 (33%) | ||
| >5 | 93 | 8 (10.6%) | 26 (34.7%) | 14 (14%) | 45 (45%) | ||
| AFP (ng/mL) | 0.723 | 0.216 | |||||
| <200 | 82 | 6 (8%) | 28 (37.3%) | 8 (8%) | 40 (40%) | ||
| ≥200 | 93 | 6 (8%) | 35 (46.7%) | 14 (14%) | 38 (38%) | ||
| Edmonson grade | 0.232 | 0.012 | |||||
| 1–2 | 132 | 7 (9.3%) | 50 (66.7%) | 12 (12%) | 63 (63%) | ||
| 3–4 | 43 | 5 (6.7%) | 13 (17.3%) | 10 (10%) | 15 (15%) | ||
| Tumor number | 0.99 | 0.000 | |||||
| Solitary | 107 | 7 (9.3%) | 40 (53.3%) | 5 (5%) | 55 (55%) | ||
| Multiple | 68 | 5 (6.7%) | 23 (30.7%) | 17 (17%) | 23 (23%) | ||
| BMI1 | 0.000 | 0.000 | |||||
| Low expression | 143 | 2 (2.7%) | 57 (76%) | 10 (10%) | 74 (74%) | ||
| High expression | 32 | 10 (13.3%) | 6 (8%) | 11 (11%) | 5 (5%) | ||
| EZH2 | 0.062 | 0.115 | |||||
| Low expression | 110 | 5 (6.7%) | 43 (57.3%) | 6 (6%) | 50 (50%) | ||
| High expression | 67 | 7 (9.3%) | 20 (26.7%) | 16 (16%) | 28 (28%) | ||
Notes:
a
χ2 test;
b
median age.